SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments (2024 - 2026)

SAB Biotherapeutics' Change in Acquisitions & Divestments history runs 3 years deep, the most recent figure standing at $74.6 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 1473.26% year-over-year to $74.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.1 million (changed N/A YoY) and the FY2025 annual result came in at $21.3 million, down 17.66% from the prior year.
• Change in Acquisitions & Divestments was $74.6 million for Q1 2026 at SAB Biotherapeutics, up from $11.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $74.6 million in Q1 2026 and bottomed at $3.8 million in Q3 2024.
• A 3-year average of $18.4 million and a median of $8.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments increased 5.38% — and 2026, when it soared 1473.26%.
• SAB Biotherapeutics' Change in Acquisitions & Divestments stood at $10.7 million in 2024, then climbed by 5.38% to $11.3 million in 2025, then surged by 561.86% to $74.6 million in 2026.
• Business Quant data shows SABS's Change in Acquisitions & Divestments at $74.6 million in Q1 2026, $11.3 million in Q4 2025, and $5.2 million in Q2 2025.